Cercar

02/10/2024 Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies
Schwartzman, S, Puig, L, Cohen, AD, Khattri, S, Jossart, C, Diaz, C, Garrelts, A, Ngantcha, M, Eberhart, N, Eleftheriadi, A, Tangsirisap, N, Schuster, C, Gottlieb, AB. Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies. Expert Opinion On Drug Safety. 2024; 23(10)DOI:10.1080/14740338.2024.2399092. PMID:39234767. IF:3.100(Q2/4D).
01/10/2024 Breakout Session and Report Back: Collaboration of Rheumatologists and Dermatologists for the Care of Patients With Psoriatic Disease
Stolnicki, DK, Coates, LC, Gollins, CE, Koppikar, S, Perez-Chada, LM, Puig, L, Ogdie, A, Deodhar, A, Ritchlin, C, Hwang, ST, Goldenstein-Schainberg, C. Breakout Session and Report Back: Collaboration of Rheumatologists and Dermatologists for the Care of Patients With Psoriatic Disease. JOURNAL OF RHEUMATOLOGY. 2024; 51DOI:10.3899/jrheum.2024-0621. PMID:39089830. IF:3.400(Q2/3D).
01/09/2024 Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial
Puig, L, Costanzo, A, de Jong, EMGJ, Torres, T, Warren, RB, Wapenaar, R, Wegner, S, Gorecki, P, Gramiccia, T, Jazra, M, Buyze, J, Conrad, C. Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial. Dermatology and Therapy. 2024; 14(9)DOI:10.1007/s13555-024-01245-6. PMID:39153060. IF:4.200(Q1/1D).
01/09/2024 A Non-Interventional, Multicenter Study to Characterize the Socio-Demographics, Clinical Characteristics, and Management of Generalized Pustular Psoriasis Patients in Spain: IMPULSE Study
Puig, L, Belloso, RI, Rivera-Díaz, R, Sánchez, JM, Fernández-Freire, LR, Sahuquillo-Torralba, A, Ruiz-Villaverde, R. A Non-Interventional, Multicenter Study to Characterize the Socio-Demographics, Clinical Characteristics, and Management of Generalized Pustular Psoriasis Patients in Spain: IMPULSE Study. DERMATOLOGY. 2024; 240(5-6)DOI:10.1159/000540019. PMID:39019021. IF:2.700(Q2/4D).
01/09/2024 Safety in Patients with Latent Tuberculosis Who Received Concomitant Anti-Tuberculosis Medications: Analysis of 11 Studies of Guselkumab in Psoriatic Disease
Puig, L, Tsai, TF, Soriano, ER, Bhutani, T, Miller, M, Kollmeier, AP, Li, S, You, Y, Petrick, M, Li, HW, Patel, H, Lavie, F, Gooderham, M, Londo o, A, Lebwohl, M, Nash, P. Safety in Patients with Latent Tuberculosis Who Received Concomitant Anti-Tuberculosis Medications: Analysis of 11 Studies of Guselkumab in Psoriatic Disease. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024 Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension
Tha i, D, Puig, L, Merola, JF, Jullien, D, Costanzo, A, Wang, M, Deherder, D, Pinto, JML, Lebwohl, M. Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).